Evidence map›Paper›PMID 26512166›Full record

ArticleAnnals of dermatology2015

Maintenance Therapy of Facial Seborrheic Dermatitis with 0.1% Tacrolimus Ointment.

Hye One Kim, Yoon Seok Yang, Hyun Chang Ko, Gyung Moon Kim, Sang Hyun Cho, Young Joon Seo, Sang Wook Son, Jong Rok Lee, Joong Sun Lee, Sung Eun Chang and 2 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of dermatology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. [Eczematous disorders in adolescents].Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete · 2016
    Review
  7. Seborrheic Dermatitis and Dandruff: A Comprehensive Review.Journal of clinical and investigative dermatology · 2015
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 8 institutions in 1 country.

Hye One KimDepartment of Dermatology, Kangnam Sacred Heart Hospital, Hallym University College of Medicine, Seoul, Korea.
Yoon Seok YangDepartment of Dermatology, Kangnam Sacred Heart Hospital, Hallym University College of Medicine, Seoul, Korea.
Hyun Chang KoDepartment of Dermatology, Pusan National University School of Medicine, Yangsan, Korea.
Gyung Moon KimDepartment of Dermatology, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Sang Hyun ChoDepartment of Dermatology, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Young Joon SeoDepartment of Dermatology, Chungnam National University School of Medicine, Daejeon, Korea.
Sang Wook SonDepartment of Dermatology, Korea University College of Medicine, Seoul, Korea.
Jong Rok LeeDepartment of Dermatology, Gachon University of Medicine and Science, Incheon, Korea.
Joong Sun LeeDepartment of Dermatology, Eulji University College of Medicine, Daejeon, Korea.
Sung Eun ChangDepartment of Dermatology, University of Ulsan College of Medicine, Seoul, Korea.
Jae We CheDepartment of Dermatology, Keimyung University School of Medicine, Daegu, Korea.
Chun Wook ParkDepartment of Dermatology, Kangnam Sacred Heart Hospital, Hallym University College of Medicine, Seoul, Korea.
Hallym University Kangnam Sacred Heart Hospital · KRCatholic University of Korea · KREulji University · KRChungnam National University · KRKeimyung University · KRKorea University · KRPusan National University · KRUlsan College · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTopical calcineurin inhibitors (TCIs) have been successfully used to treat seborrheic dermatitis (SD) patients. Meanwhile, treatment of atopic dermatitis (AD) with low-dose, intermittent TCI has been proved to reduce disease flare-ups. This regimen is known as a maintenance treatment.

objectiveThe aim of this trial was to investigate the efficacy and tolerability of a maintenance treatment with tacrolimus ointment in patients with facial SD.

methodsDuring the initial stabilization period, patients with facial SD or AD applied 0.1% tacrolimus ointment twice daily for up to 4 weeks. Clinical measurements were evaluated on either in the whole face or on separate facial regions. When an investigator global assessment score 1 was achieved, the patient applied tacrolimus twice weekly for 20 weeks. We also compared our results with recent published data of placebo controlled study to allow an estimation of the placebo effect.

resultsThe time to the first relapse during phase II was similar in both groups otherwise significantly longer than the placebo group. The recurrence-free curves of two groups were not significantly different from each other; otherwise the curve of the placebo group was significantly different. There were no significant differences between the 2 groups in the number of DEs, and treatment days for disease exacerbations (DEs). The adverse event profile was also similar between the 2 groups. During the 20 weeks of treatment, the study population tolerated tacrolimus ointment well.

conclusionThe results of this study suggest that maintenance treatment with tacrolimus may be effective in preventing the occurrence of facial SD exacerbations.

Indexed as

Maintenance therapySeborrheic dermatitisTacrolimus ointment

Identifiers

PMID26512166
PMCPMC4622886
OpenAlexW1893668115

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.